Global Biodefense Market Outlook, 2027: Anthrax Expected to Grow at a Significant Rate Owing to Increased Investments on Production and Stockpiling by Government Agencies -

DUBLIN--()--The "Biodefense - Global Market Outlook (2018-2027)" report has been added to's offering.

The Global Biodefense market accounted for $5.47 billion in 2018 and is expected to reach $8.85 billion by 2027, growing at a CAGR of 5.5% during the forecast period.

Some of the key factors propelling the market growth are rising investment by the governments in developed countries and technological advancements. However, less penetration in developing and underdeveloped countries is the restraining factor for the growth of the market.

By product, vaccines segment is segregated into anthrax, antibiotics, botulism, E-Bola, eye shield, immunization vaccine, nuclear/radiation, smallpox, and zika. Anthrax segment is expected to grow at the significant market share during the forecast period owing to the increased investment on production and stockpiling of anthrax vaccine by government agencies such as the Centre for Disease Control (CDC) and Department of Defense among others.

On the basis of geography, North America is anticipated to hold considerable market share during the forecast period due to increase spending by the governments across the globe to develop and store sufficient vaccines against anthrax and U.S government implementing the number of initiatives that assist them in reinforcing security against biological threats.

Some of the key players in Biodefense Market include Xoma Corporation, Altimmune Inc, Bavarian Nordic, Cleveland BioLabs, Dynavax Technologies Inc, Dynport Vaccine Company LLC (DVC), Elusys Therapeutics, Emergent BioSolutions Inc, Ichor Medical Systems, Nanotherapeutics, Ology Bioservices, PathSensors Inc and Siga Technologies Inc.

What the report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2017, 2018, 2019, 2023 and 2027
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic analysis: Drivers and Constraints, Product/Technology Analysis, Porter's five forces analysis, SWOT analysis, etc.
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Key Topics Covered

1 Executive Summary

2 Preface

3 Market Trend Analysis

3.1 Introduction

3.2 Drivers

3.3 Restraints

3.4 Opportunities

3.5 Threats

3.6 Product Analysis

3.7 Application Analysis

3.8 Emerging Markets

3.9 Impact of COVID-19

4 Porters Five Force Analysis

4.1 Bargaining power of suppliers

4.2 Bargaining power of buyers

4.3 Threat of substitutes

4.4 Threat of new entrants

4.5 Competitive rivalry

5 Global Biodefense Market, By Product

5.1 Introduction

5.2 Vaccines

5.2.1 Anthrax

5.2.2 Antibiotics

5.2.3 Botulism

5.2.4 E-Bola

5.2.5 Eye Shield

5.2.6 Immunization Vaccine

5.2.7 Nuclear/Radiation

5.2.8 Smallpox

5.2.9 Zika

5.3 Biothreat detection devices

5.3.1 Assays and Reagents

5.3.2 Detectors/triggering devices

5.3.3 Identifiers

5.3.4 Samplers

6 Global Biodefense Market, By Sales Channel

6.1 Introduction

6.2 Direct Sales

6.3 In Direct Sales

7 Global Biodefense Market, By Application

7.1 Introduction

7.2 Military

7.3 Civilian

8 Global Biodefense Market, By Geography

8.1 Introduction

8.2 North America

8.2.1 US

8.2.2 Canada

8.2.3 Mexico

8.3 Europe

8.3.1 Germany

8.3.2 UK

8.3.3 Italy

8.3.4 France

8.3.5 Spain

8.3.6 Rest of Europe

8.4 Asia-Pacific

8.4.1 Japan

8.4.2 China

8.4.3 India

8.4.4 Australia

8.4.5 New Zealand

8.4.6 South Korea

8.4.7 Rest of Asia-Pacific

8.5 South America

8.5.1 Argentina

8.5.2 Brazil

8.5.3 Chile

8.5.4 Rest of South America

8.6 Middle East & Africa

8.6.1 Saudi Arabia

8.6.2 UAE

8.6.3 Qatar

8.6.4 South Africa

8.6.5 Rest of Middle East & Africa

9 Key Developments

9.1 Agreements, Partnerships, Collaborations and Joint Ventures

9.2 Acquisitions & Mergers

9.3 New Product Launch

9.4 Expansions

9.5 Other Key Strategies

10 Company Profiling

10.1 Xoma Corporation

10.2 Altimmune Inc.

10.3 Bavarian Nordic

10.4 Cleveland BioLabs

10.5 Dynavax Technologies Inc.

10.6 Dynport Vaccine Company LLC (DVC)

10.7 Elusys Therapeutics

10.8 Emergent BioSolutions Inc.

10.9 Ichor Medical Systems

10.10 Nanotherapeutics

10.11 Ology Bioservices

10.12 PathSensors Inc.

10.13 Siga Technologies Inc.

For more information about this report visit

Laura Wood, Senior Press Manager

For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Laura Wood, Senior Press Manager

For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900